سعر تيديميرب 200مجم 6 اقراص 2022

Tedizolid phosphate 200 mg film-coated tablets, 6 tablets (one 6-day course), by Hikma; oxazolidinone antibiotic for acute bacterial skin and skin structure infections.

• Acute bacterial skin and skin structure infections (ABSSSI) in adults, adolescents and children weighing at least 35 kgEuropean Medicines Agency (EPAR product information)

• Most frequent in phase 3 studies: nausea (6.9%), headache (3.5%), diarrhoea (3.2%), vomiting (2.3%), generally mild to moderate.International label, same formulation · European Medicines Agency (EPAR product information)

• Hypersensitivity to tedizolid phosphate or any excipient.International label, same formulation · European Medicines Agency (EPAR product information)

• Safety/efficacy not investigated in neutropenia (<1 000 cells/mm3); consider alternatives.International label, same formulation · European Medicines Agency (EPAR product information)
• Myelosuppression (thrombocytopenia, decreased haemoglobin/neutrophils) observed; mitochondrial toxicity effects (lactic acidosis, anaemia, optic/peripheral neuropathy) reported with another oxazolidinone over longer courses; report visual symptoms promptly.International label, same formulation · European Medicines Agency (EPAR product information)
• Caution in patients hypersensitive to other oxazolidinones; Clostridioides difficile-associated diarrhoea reported.International label, same formulation · European Medicines Agency (EPAR product information)

• BCRP substrates (e.g. imatinib, lapatinib, methotrexate, rosuvastatin)Oral tedizolid may inhibit intestinal BCRP and increase exposure to BCRP substrates; interrupt the co-administered substrate during the 6-day course if possible.European Medicines Agency (EPAR product information)
• Monoamine oxidase-related agents (serotonergic or adrenergic drugs)Tedizolid is a reversible non-selective MAO inhibitor in vitro; limited data with serotonergic/adrenergic agents.European Medicines Agency (EPAR product information)

• No data in pregnant women; developmental effects in mice and rats; preferable to avoid in pregnancy.International label, same formulation · European Medicines Agency (EPAR product information)
• Unknown whether excreted in human milk (excreted in rat milk); decide whether to stop breast-feeding or therapy.International label, same formulation · European Medicines Agency (EPAR product information)

• Tedizolid phosphate: Prodrug converted to tedizolid; binds 50S ribosomal subunit and inhibits bacterial protein synthesis.